Semaglutide for PCOS: What the Research Shows About Weight and Hormones

Polycystic ovary syndrome (PCOS) is one of the most common hormonal conditions in women, affecting an estimated 8-13% of those of reproductive age. It brings with it a frustrating set of overlapping challenges: difficulty losing weight, insulin resistance, elevated male hormones, irregular periods, and, for many women, a sense that their body is working against them.

Weight management sits at the center of PCOS care. Even modest weight loss can improve insulin sensitivity, lower androgen levels, and restore more regular menstrual cycles. But losing weight with PCOS is genuinely harder than it is for women without the condition, partly because of how the syndrome affects appetite, metabolism, and fat storage.

This is one of the reasons interest in GLP-1 receptor agonists like semaglutide has grown among women with PCOS and the providers who treat them. The research is still developing, but the early findings are promising.

> Important disclaimer: Semaglutide is not FDA-approved specifically for PCOS treatment. Compounded semaglutide is also not FDA-approved. Any use of semaglutide for PCOS management is off-label and requires a full evaluation by a licensed healthcare provider. This article is for educational purposes only and does not constitute medical advice.

---

What Is PCOS and Why Does Weight Matter?

PCOS is a complex endocrine disorder defined by a combination of features: elevated androgens (male hormones like testosterone), irregular or absent ovulation, and in many cases, polycystic-appearing ovaries on ultrasound. Not every woman with PCOS has all three features, and the condition presents very differently from person to person.

Insulin resistance is present in up to 70-80% of women with PCOS, including those who are lean. When cells become resistant to insulin's signals, the pancreas compensates by producing more insulin. This excess insulin stimulates the ovaries to produce more androgens, which disrupts the normal hormonal feedback loop that governs ovulation and menstrual cycling.

The result is a difficult feedback loop: excess androgens promote fat storage, particularly in the abdomen. Increased abdominal fat worsens insulin resistance. Worsening insulin resistance drives androgen production higher. Weight gain and PCOS perpetuate each other.

Treatments that interrupt this cycle at the insulin resistance level, which is what [GLP-1 medications](/resources/what-are-glp1-medications-complete-guide) do well, have logical appeal for PCOS management.

---

How GLP-1 Medications Work in PCOS

GLP-1 receptor agonists like semaglutide were developed primarily for type 2 diabetes and obesity. They work by mimicking the glucagon-like peptide-1 hormone, which is released naturally in the gut after eating. The effects relevant to PCOS include:

Improving Insulin Sensitivity

Semaglutide reduces glucose-stimulated insulin secretion by encouraging the pancreas to release insulin more efficiently in response to meals, rather than continuously. This decreases the chronic hyperinsulinemia (excess insulin) that drives androgen overproduction in PCOS.

By reducing circulating insulin levels, GLP-1 medications help interrupt the central hormonal disruption in PCOS at its source.

Reducing Body Weight and Visceral Fat

The substantial weight loss produced by semaglutide directly addresses one of the drivers of PCOS severity. Adipose tissue, particularly abdominal fat, is itself hormonally active: it produces androgens and inflammatory signals that worsen insulin resistance. Reducing body weight and visceral fat load improves the overall metabolic and hormonal environment.

Effects on Androgen Levels

Research suggests that GLP-1 medications may help reduce circulating testosterone and other androgen markers in women with PCOS. This is likely an indirect effect rather than a direct one: as insulin drops, the ovarian stimulus for androgen production decreases, and hormonal balance begins to shift.

---

What the Research Shows

Several clinical trials and systematic reviews have examined GLP-1 receptor agonists specifically in women with PCOS. The evidence is not yet from phase 3 trials powered specifically for PCOS as a primary endpoint, but the findings are consistently encouraging.

Semaglutide Combined with Metformin in PCOS

A prospective randomized controlled trial published in Reproductive Biology and Endocrinology evaluated the effects of combining semaglutide and metformin in overweight and obese women with PCOS [1]. The researchers found significant improvements in body weight, metabolic parameters including insulin resistance markers, and reproductive outcomes. Participants showed improvements in menstrual regularity and hormonal profiles compared to baseline.

This study is particularly relevant because it used semaglutide directly, rather than other GLP-1 agonists, and assessed outcomes that matter to PCOS patients beyond just weight loss.

GLP-1 Receptor Agonists vs. Metformin: Meta-Analysis

A 2026 systematic review and meta-analysis published in Cureus compared GLP-1 receptor agonists to metformin, which is the standard first-line medication for PCOS metabolic management, in women with PCOS [2]. The meta-analysis found that GLP-1 receptor agonists were superior to metformin for weight reduction and showed comparable or better improvement in metabolic markers including fasting insulin and HOMA-IR (a measure of insulin resistance).

This is meaningful context: metformin has decades of evidence in PCOS. GLP-1 medications competing with or outperforming metformin for the metabolic features of PCOS is a clinically significant finding.

GLP-1 Agonists for Weight and Hormonal Regulation: Meta-Analysis of RCTs

A meta-analysis published in the Journal of Diabetes and Its Complications pooled randomized controlled trial data on GLP-1 agonists specifically in women with obesity and PCOS [3]. The analysis found meaningful reductions in body weight, testosterone levels, fasting insulin, and improvements in menstrual cyclicity across studies. The authors concluded that GLP-1 agonists are both effective and well-tolerated in this population.

While the trials included in these meta-analyses used a range of GLP-1 agents (including liraglutide and exenatide, not only semaglutide), the class effects appear consistent.

---

What GLP-1 Medications Do Not Do for PCOS

It is important to be clear about what GLP-1 medications are not.

They are not a fertility treatment. Some women with PCOS experience improved menstrual regularity on GLP-1 medications, but this is not the same as treating infertility. If you are trying to conceive, you need specialist input from a reproductive endocrinologist, not just a weight loss program.

They are not approved for PCOS. The FDA approved semaglutide for type 2 diabetes (Ozempic) and chronic weight management (Wegovy) in adults with obesity or overweight with at least one weight-related condition. PCOS is not an FDA-approved indication for semaglutide. Any prescribing for PCOS management is off-label.

They do not treat the root cause of PCOS. PCOS is a complex condition with genetic, metabolic, and hormonal dimensions. GLP-1 medications address the insulin resistance and weight components meaningfully, but they do not address every aspect of the syndrome.

Compounded semaglutide is not FDA-approved. Compounded medications are prepared by licensed compounding pharmacies and prescribed by licensed providers based on individual patient evaluation. They are not generics, and they are not FDA-approved products.

---

Who Might Be a Candidate

If you have PCOS and also meet the general criteria for GLP-1 medication prescribing, a conversation with your provider is worthwhile. General candidates for [compounded semaglutide](/resources/compounded-semaglutide-what-it-is) through a telehealth program typically include adults with:

• A BMI of 30 or higher, or BMI 27 or higher with at least one weight-related health condition
• No contraindications (personal or family history of MTC, MEN2, or severe GI disorders)
• Commitment to combining medication with dietary and lifestyle changes

For women with PCOS, the presence of insulin resistance and metabolic complications may make the case for GLP-1 treatment particularly strong - though this determination belongs to your provider, not to a general guide like this one.

Your provider should be aware of your full picture: PCOS diagnosis, current medications (including metformin, if applicable), reproductive goals, and any prior treatments. The combination of metformin and semaglutide was studied in the Chen et al. trial referenced above, and your provider may find this combination appropriate for your situation.

---

Key Takeaways

• PCOS is closely linked to insulin resistance, and treatments that reduce insulin and body weight can meaningfully improve PCOS symptoms.
• GLP-1 medications like semaglutide improve insulin sensitivity, promote significant weight loss, and appear to reduce androgen levels in women with PCOS.
• Clinical trial data, including a randomized controlled trial using semaglutide directly, supports the use of GLP-1 receptor agonists in overweight and obese women with PCOS.
• Meta-analyses show GLP-1 agonists compare favorably to metformin for weight and metabolic outcomes in PCOS.
• Semaglutide is not FDA-approved for PCOS, and its use in this context is off-label. Compounded semaglutide is also not FDA-approved.
• A licensed healthcare provider who understands your full medical history is the right person to determine whether GLP-1 treatment is appropriate for you.

---

Starting Your Weight Loss Journey

If you have PCOS and are looking for a medically supervised approach to weight management, Prescriva connects you with licensed providers who conduct a thorough evaluation and develop a plan specific to your needs.

Ready to explore your options? [Check your eligibility](/quiz)

---

> Disclaimer: This article is for educational purposes only and does not constitute medical advice. Semaglutide is not FDA-approved for PCOS treatment. Compounded semaglutide is not FDA-approved. Use of GLP-1 medications for PCOS management is off-label. Individual results vary and depend on a combination of medication, diet, exercise, and other lifestyle factors. Prescriva's compounded medications are prescribed by licensed healthcare providers following individual medical evaluation and dispensed by licensed 503A compounding pharmacies. Blue Oak Services LLC dba Prescriva is a Management Services Organization (MSO) that does not practice medicine. Always consult your healthcare provider before starting any new medication.

---

References

1. Chen H, Li Y, Zhang M, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. *Reprod Biol Endocrinol.* 2025. [PMID: 40713699](https://pubmed.ncbi.nlm.nih.gov/40713699/)

1. Almubaddil K, Al-Qadhi M, Hariri M, et al. Effects of GLP-1 Receptor Agonists vs Metformin in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. *Cureus.* 2026. [PMID: 41873309](https://pubmed.ncbi.nlm.nih.gov/41873309/)

1. Austregésilo de Athayde De Hollanda Morais B, Gadelha MO, Veloso LC, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials. *J Diabetes Complications.* 2024. [PMID: 39178623](https://pubmed.ncbi.nlm.nih.gov/39178623/)